Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity.

Parveen, Shahida; Hanif, Muhammad; Leung, Yee Fun; Tong, Ki; Yang, Annie; Astin, Jonathan; De Zoysa, Gayan; Steel, Tasha R; Goodman, David; Hanif, Muhammad; Soehnel, Tilo; Sarojini Amma, Vijayalekshmi; Jamieson, Stephen; Hartinger, Christian

dc.contributor.author	Parveen, Shahida	en
dc.contributor.author	Hanif, Muhammad	en
dc.contributor.author	Leung, Yee Fun	en
dc.contributor.author	Tong, Ki	en
dc.contributor.author	Yang, Annie	en
dc.contributor.author	Astin, Jonathan	en
dc.contributor.author	De Zoysa, Gayan	en
dc.contributor.author	Steel, Tasha R	en
dc.contributor.author	Goodman, David	en
dc.contributor.author	Hanif, Muhammad	en
dc.contributor.author	Soehnel, Tilo	en
dc.contributor.author	Sarojini Amma, Vijayalekshmi	en
dc.contributor.author	Jamieson, Stephen	en
dc.contributor.author	Hartinger, Christian	en
dc.date.accessioned	2020-01-12T22:56:07Z	en
dc.date.issued	2019-10	en
dc.identifier.citation	Chemical Communications 55(80):12016-12019 Oct 2019	en
dc.identifier.issn	1359-7345	en
dc.identifier.uri	http://hdl.handle.net/2292/49615	en
dc.description.abstract	Redox-modulating anticancer drugs allow the exploitation of altered redox biology observed in many cancer cells. We discovered dinuclear RhIII(Cp) and IrIII(Cp) complexes that have in vitro anticancer activity superior to cisplatin and the investigational drug IT-139, while being less toxic in haemolysis and in vivo zebrafish models. The mode of action appears to be related to DNA damage and ROS-mediated stress pathways.	en
dc.format.medium	Print	en
dc.language	eng	en
dc.relation.ispartofseries	Chemical communications (Cambridge, England)	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.subject	Cell Line, Tumor	en
dc.subject	Animals	en
dc.subject	Zebrafish	en
dc.subject	Humans	en
dc.subject	Mice	en
dc.subject	DNA Damage	en
dc.subject	Hemolysis	en
dc.subject	Cisplatin	en
dc.subject	Iridium	en
dc.subject	Rhodium	en
dc.subject	Ruthenium	en
dc.subject	Reactive Oxygen Species	en
dc.subject	Antineoplastic Agents	en
dc.subject	Ligands	en
dc.subject	Drug Screening Assays, Antitumor	en
dc.subject	Cell Survival	en
dc.subject	Structure-Activity Relationship	en
dc.subject	Oxidation-Reduction	en
dc.subject	Coordination Complexes	en
dc.title	Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity.	en
dc.type	Journal Article	en
dc.identifier.doi	10.1039/c9cc03822a	en
pubs.issue	80	en
pubs.begin-page	12016	en
pubs.volume	55	en
dc.rights.holder	Copyright: The Royal Society of Chemistry 2019	en
pubs.end-page	12019	en
pubs.publication-status	Published	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.subtype	Journal Article	en
pubs.elements-id	780855	en
pubs.org-id	Medical and Health Sciences	en
pubs.org-id	Medical Sciences	en
pubs.org-id	Auckland Cancer Research	en
pubs.org-id	Pharmacology	en
pubs.org-id	Science	en
pubs.org-id	Chemistry	en
pubs.org-id	Science Research	en
pubs.org-id	Maurice Wilkins Centre (2010-2014)	en
dc.identifier.eissn	1364-548X	en
pubs.record-created-at-source-date	2019-09-10	en
pubs.dimensions-id	31498360	en